Muhammad Ismail

henan university

H指数:20

被引数:1,372

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

mTOR-siRNA-conjugated and Gboxin-loaded micelles for mitochondrial dysfunction-driven synergistic glioblastoma therapy

mTOR-siRNA缀合且负载Gboxin的胶束，用于线粒体功能障碍驱动的协同胶质母细胞瘤疗法

Biomaterials

IF12.9

2025-12-100

PRE

Enhancing lipid nanoparticles-mediated RNA delivery to glioblastoma via targeted strategies

通过靶向策略增强脂质纳米颗粒介导的RNA向胶质母细胞瘤的递送

Journal of Controlled Release

IF11.5

2025-11-270

PRE

Clinical translation of nanomedicines for brain diseases: Current challenges and future directions

脑部疾病纳米药物的临床转化：当前挑战与未来方向

Journal of Controlled Release

IF11.5

2025-11-190

PRE

Pattern of Pharmaceutical Poisoning in the Perak Population with Special Reference to the Age and Poisoning Mode Impact

马来西亚霹雳州人口中药物中毒的模式，特别关注年龄和中毒方式的影响

Risk Management and Healthcare Policy

IF2

2025-11-180

OAAI

Non-cationic carriers for siRNA delivery: Current progress and potential applications

非阳离子载体在siRNA递送中的应用：当前进展与潜在应用

Journal of Controlled Release

IF11.5

2025-10-270

PRE

Tumor cell-derived engineered exosome enhances effective immunotherapy for orthotopic glioblastoma and its recurrences

肿瘤细胞来源的工程化外泌体增强了正位性胶质母细胞瘤及其复发的有效免疫疗法

NANO TODAY

IF10.9

2025-06-101

OAAI

Stimuli-Responsive Polymeric Nanocarriers Accelerate On-Demand Drug Release to Combat Glioblastoma

BIOMACROMOLECULES

IF5.4

2024-09-116

PRE

Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy

脑靶向CRISPR/Cas9纳米药物用于有效的胶质母细胞瘤治疗

JOURNAL OF CONTROLLED RELEASE

IF11.5

2022-11-0120

PRE

Biomimetic Dp44mT-nanoparticles selectively induce apoptosis in Cu-loaded glioblastoma resulting in potent growth inhibition

BIOMATERIALS

IF12.9

2022-10-0127

PRE

Arsenic Prodrug-Mediated Tumor Microenvironment Modulation Platform for Synergetic Glioblastoma Therapy

ACS APPLIED MATERIALS & INTERFACES

IF8.2

2022-08-0311

PRE

Carbon dots supported single Fe atom nanozyme for drug-resistant glioblastoma therapy by activating autophagy-lysosome pathway

碳点负载单Fe原子纳米酶激活自噬-溶酶体途径治疗耐药胶质母细胞瘤

NANO TODAY

IF10.9

2022-08-01118

PRE

Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma

BIOMATERIALS

IF12.9

2022-08-0160

PRE

Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy

JOURNAL OF CONTROLLED RELEASE

IF11.5

2022-05-0154

PRE

Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy

ACS NANO

IF16

2022-03-3037

PRE

Nanotechnology-Based Strategies for Early Diagnosis of Central Nervous System Disorders

ADVANCED NANOBIOMED RESEARCH

IF4.4

2021-07-3123

OAAI

ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways

NANOSCALE

IF5.1

2021-01-0120

PRE

Vitamin E-based prodrug self-delivery for nanoformulated irinotecan with synergistic antitumor therapeutics

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2020-03-0118

PREAI

Synthetic dimeric-drug phospholipid: a versatile liposomal platform for cancer therapy

CHEMICAL COMMUNICATIONS

IF4.2

2020-01-015

PREAI

Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria

基于青蒿琥酯-肝素缀合物的纳米胶囊具有改善的抗疟疾药代动力学

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2019-05-0149

PREAI

Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2019-04-0121

PREAI

Muhammad Ismail

个人简介

教育背景

工作经历

荣誉奖项

研究方向